Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day
WuXi XDC and BioDlink jointly hosted the 2026 Open Day, marking their first flagship customer-facing event following the strategic integration. The event brought together biotech customers, industry leaders and innovators to explore how an...
WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO
Revenue increased by 46.7% YoY to RMB 5,944 million Gross profit surged by 72.5% YoY to RMB 2,139 million, with its margin of 36.0%, a 5.4 percentage points increase compared to 2024 Adjusted net profit increased by 69.9% YoY to RMB 1,559 million,...
WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform
SHANGHAI, Feb. 27, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other...
Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform
WILMINGTON, Del., Feb. 27, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with WuXi XDC Cayman Inc. ("WuXi XDC", stock...
WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories
SHANGHAI, May 20, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced that the...
WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025
SHANGHAI, March 13, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates...
WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs
SHANGHAI and SEOUL, South Korea , March 11, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in...
WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs)...